Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Feb 13;69(2):e0108724.
doi: 10.1128/aac.01087-24. Epub 2025 Jan 16.

New Perspectives on Antimicrobial Agents: Omadacycline for community-acquired pneumonia, skin and soft tissue infections, and nontuberculous mycobacteria (focus on M. abscessus)

Thomas M File Jr  1   2 , Julio A Ramirez  3   4 , Ashley M Wilde  4
Affiliations
Review

New Perspectives on Antimicrobial Agents: Omadacycline for community-acquired pneumonia, skin and soft tissue infections, and nontuberculous mycobacteria (focus on M. abscessus)

Thomas M File Jr et al. Antimicrob Agents Chemother. .

Abstract

Omadacycline is a novel antimicrobial belonging to the tetracycline class. It has the ability to evade both efflux and ribosomal methylation types of resistance and therefore has an expanded spectrum compared to other tetracycline agents. Omadacycline is active against a number of multidrug-resistant bacteria, including macrolide and doxycycline-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus, and several enteric gram-negative bacilli. It also has activity against many nontuberculous mycobacterium (NTM) species. It is available both orally and intravenously, which allows for feasible switch therapy. This review will assess the antimicrobial activity, pharmacology, safety, and clinical efficacy of omadacycline and present the opinions of the authors on where to position omadacycline for clinical practice.

Keywords: clinical use; omadacycline; pneumonia; skin infections.

PubMed Disclaimer

Conflict of interest statement

T.M.F. has served as a consultant for ThermoFisher, MicroGenDx, HealthTrackRx, Shionogi, and Paratek. He is a member of a DSMB for a clinical trial sponsored by Eagle Pharmaceuticals. J.A.R. and A.M.W. declare no conflicts of interest.

Figures

Fig 1
Fig 1
Algorithm for use of omadacycline for bacterial causes of CAP.
Fig 2
Fig 2
Use of omadacycline for cellulitis.
See this image and copyright information in PMC

References

    1. Nuzyra: highlights of prescribing information. Available from: https://www.nuzyra.com/nuzyra-pi.pdf
    1. Paratek pharmaceuticals announces FDA orphan drug designation for NUZYRA (omadacycline) for the treatment of infections caused by nontuberculous mycobacteria. 2021. Available from: https://www.globenewswire.com/en/news-release/2021/08/18/2283087/33636/e...
    1. Heidrich CG, Mitova S, Schedlbauer A, Connell SR, Fucini P, Steenbergen JN, Berens C. 2016. The novel aminomethylcycline omadacycline has high specificity for the primary tetracycline-binding site on the bacterial ribosome. Antibiotics (Basel) 5:32. doi:10.3390/antibiotics5040032 - DOI - PMC - PubMed
    1. Tanaka SK, Steenbergen J, Villano S. 2016. Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic. Bioorg Med Chem 24:6409–6419. doi:10.1016/j.bmc.2016.07.029 - DOI - PubMed
    1. Macone AB, Caruso BK, Leahy RG, Donatelli J, Weir S, Draper MP, Tanaka SK, Levy SB. 2014. In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline. Antimicrob Agents Chemother 58:1127–1135. doi:10.1128/AAC.01242-13 - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources